Ascendiant Capital Markets Forecasts Strong Price Appreciation for Lucid Diagnostics (NASDAQ:LUCD) Stock

Lucid Diagnostics (NASDAQ:LUCD) had its price target raised by Ascendiant Capital Markets from $7.00 to $7.50 in a report issued on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other equities research analysts have also recently issued reports on LUCD. BTIG Research set a $2.00 price target on shares of Lucid Diagnostics in a research note on Tuesday, March 25th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $2.00 price target on shares of Lucid Diagnostics in a report on Wednesday, March 26th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Lucid Diagnostics in a research report on Friday, April 11th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $3.50.

Lucid Diagnostics Stock Performance

LUCD stock opened at $1.29 on Monday. The stock’s 50 day moving average price is $1.41 and its 200 day moving average price is $1.08. The firm has a market cap of $117.07 million, a P/E ratio of -1.13 and a beta of 1.26. Lucid Diagnostics has a 1 year low of $0.63 and a 1 year high of $1.80.

Institutional Trading of Lucid Diagnostics

A number of institutional investors and hedge funds have recently bought and sold shares of LUCD. Sargent Investment Group LLC acquired a new position in shares of Lucid Diagnostics during the 4th quarter valued at $442,000. XML Financial LLC purchased a new stake in Lucid Diagnostics during the 1st quarter worth $266,000. Citadel Advisors LLC purchased a new position in Lucid Diagnostics in the 4th quarter valued at about $98,000. Sunbelt Securities Inc. acquired a new stake in shares of Lucid Diagnostics during the fourth quarter valued at about $67,000. Finally, Lido Advisors LLC increased its position in shares of Lucid Diagnostics by 40.0% during the fourth quarter. Lido Advisors LLC now owns 140,016 shares of the company’s stock worth $115,000 after acquiring an additional 40,000 shares during the last quarter. Institutional investors and hedge funds own 74.01% of the company’s stock.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.